Plant Name: Dioscorea japonica
Taxonomic Information:
Plant ID: NPO1103
Plant Latin Name: Dioscorea japonica
Taxonomy Genus: Dioscorea
Taxonomy Family: Dioscoreaceae
Plant External Links:
NCBI TaxonomyDB:
4673
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Korea; ChinaTraditional Medicine System:
TCM; KampoMedicinal Functions:
Contraceptive; Miscellany; Tonic
Geographical Distribution:
South Korea; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR4; FFAR1; GPR35; | |
| NPSR1; | |
| RECQL; TDP1; TERT; GLO1; PGD; ALOX12; AKR1B1; HSD17B2; HSD17B10; ALOX15; HPGD; NOX4; APEX1; POLB; | |
| ACHE; | |
| BCL2; | |
| TOP2A; | |
| TEK; NUAK1; INSR; AXL; KDR; FLT3; CDK1; EGFR; PIM1; MET; SRC; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; | |
| TYR; | |
| KDM4E; | |
| F10; F2; | |
| AHR; NFKB1; | |
| FUT7; | |
| DNMT1; | |
| ABCB1; | |
| SLC22A6; | |
| LMNA; FABP3; SMAD3; FABP4; FABP5; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.211E-08 | 6.420E-06 | AXL, EGFR, F10, INSR, MET, NOX4, SRC, TEK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.119E-07 | 2.437E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.996E-07 | 5.829E-05 | ABCB1, AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.385E-07 | 6.500E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 4.684E-07 | 8.430E-05 | AKR1B1, ALOX12, ALOX15, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, KDM4E, NOX4, PGD, TYR |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.270E-06 | 1.934E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.399E-06 | 2.107E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.505E-06 | 2.244E-04 | F2, FFAR4, NFKB1, PPARA, SMAD3, TEK |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.362E-06 | 3.384E-04 | EGFR, INSR, KDR |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.522E-06 | 3.566E-04 | ALOX15, EGFR, FFAR4, KDR, NOX4, SRC, TEK |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 2.611E-06 | 3.668E-04 | AHR, AXL, BCL2, CSNK2A1, EGFR, PPARA, SRC, TOP2A |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.367E-06 | 4.390E-04 | ABCB1, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.367E-06 | 4.390E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.614E-06 | 4.602E-04 | BCL2, CA2, CA7, F2, KDR, NPSR1, SRC |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 3.806E-06 | 4.791E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 4.599E-06 | 5.690E-04 | BCL2, NOX4, SRC, TERT |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.599E-06 | 5.690E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 8.505E-06 | 9.645E-04 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, PPARA, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.488E-06 | 1.023E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.488E-06 | 1.023E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.488E-06 | 1.023E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.040E-05 | 1.116E-03 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.139E-05 | 1.202E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.233E-05 | 1.272E-03 | APEX1, CYP1A1, CYP1B1, EGFR, FLT3, NFKB1, NOX4, SRC |
| MF | Unclassified; | GO:0004872; receptor activity | 1.430E-05 | 1.455E-03 | AHR, AXL, EGFR, F2, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, PPARA, TEK |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.550E-05 | 1.549E-03 | ALOX12, ALOX15, HPGD |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.680E-05 | 1.659E-03 | AHR, AKR1B1, APEX1, AURKB, BCL2, CDK1, CSNK2A1, DNMT1, FABP5, HPGD, HSPA1A, L3MBTL1, LMNA, NFKB1, NUAK1, PIM1, POLB, PPARA, RECQL, SMAD3, SRC, TERT, TOP2A |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.391E-05 | 2.225E-03 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 2.548E-05 | 2.280E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 2.738E-05 | 2.404E-03 | CDK1, CYP1A2, EGFR, TERT |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.841E-05 | 2.426E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.841E-05 | 2.426E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.841E-05 | 2.426E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 3.119E-05 | 2.620E-03 | ALOX15, HSPA1A, MET, NOX4, SMAD3, TEK |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 3.128E-05 | 2.620E-03 | AHR, PPARA, TERT |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 3.369E-05 | 2.786E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 3.398E-05 | 2.792E-03 | AKR1B1, HPGD, HSD17B10, HSD17B2, PGD |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.642E-05 | 2.970E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 4.126E-05 | 3.315E-03 | AURKB, BCL2, MET, PPARA, SRC, TERT |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 4.475E-05 | 3.538E-03 | AKR1B1, APEX1, IGF1R, INSR, NFKB1, SRC |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.828E-05 | 3.768E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.819E-05 | 3.768E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.828E-05 | 3.768E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 5.189E-05 | 3.978E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 5.249E-05 | 4.011E-03 | F2, FLT3, KDR, TEK |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.670E-05 | 4.272E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.242E-05 | 4.639E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0032870; cellular response to hormone stimulus | 9.015E-05 | 6.332E-03 | APEX1, EGFR, FFAR4, FLT3, INSR, NFKB1, SRC |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.131E-05 | 6.352E-03 | AKR1B1, EGFR, HPGD, TERT |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.432E-05 | 6.479E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 9.609E-05 | 6.539E-03 | AKR1B1, CYP1B1, F2, FLT3 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 9.829E-05 | 6.668E-03 | AXL, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.090E-04 | 7.126E-03 | FLT3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.106E-04 | 7.188E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 1.158E-04 | 7.481E-03 | ALOX12, CYP1B1, KDR, TEK, TERT |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.325E-04 | 8.246E-03 | AHR, CSNK2A1, KDR |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.385E-04 | 8.545E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.411E-04 | 8.636E-03 | ACHE, EGFR, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.435E-04 | 8.703E-03 | AHR, AXL, BCL2, EGFR, NFKB1, SMAD3, TOP2A, TYR |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.455E-04 | 8.727E-03 | PPARA, SMAD3, TERT |
| BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.455E-04 | 8.727E-03 | INSR, PPARA, SRC |
| MF | GO:0005488; binding | GO:0003682; chromatin binding | 1.516E-04 | 9.068E-03 | APEX1, CDK1, DNMT1, EGFR, L3MBTL1, NFKB1, SMAD3, TOP2A |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.536E-04 | 9.130E-03 | ACHE, BCL2, FLT3, HPGD, NFKB1, SLC22A6, SMAD3, TERT, TOP2A, TYR |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.536E-04 | 9.130E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, PPARA, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.555E-04 | 9.175E-03 | BCL2, EGFR, MET, PPARA, SMAD3 |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1.592E-04 | 9.319E-03 | BCL2, HSPA1A, TERT |
| BP | GO:0009987; cellular process | GO:0001775; cell activation | 1.605E-04 | 9.369E-03 | AXL, BCL2, EGFR, F2, FABP5, FLT3, FUT7, HSPA1A, NFKB1, SMAD3, SRC |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.612E-04 | 9.385E-03 | ACHE, AKR1B1, APEX1, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.661E-04 | 9.648E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.345E-09 | 3.681E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.916E-07 | 2.049E-05 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.437E-07 | 2.527E-05 | INSR, BCL2, TEK, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 3.166E-06 | 8.284E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.818E-06 | 8.284E-05 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, MET, EGFR, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.125E-06 | 1.149E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.779E-06 | 1.527E-04 | INSR, KDR, BCL2, TEK, MET, EGFR, NFKB1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.691E-07 | 1.328E-05 | CA12, CA2, CA4, CA7 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.211E-05 | 2.113E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.134E-05 | 4.473E-04 | SRC, KDR, BCL2, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 5.163E-05 | 6.604E-04 | SRC, MET, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.798E-04 | 1.882E-03 | SMAD3, FLT3, BCL2, MET, EGFR, NFKB1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.751E-05 | 4.318E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.477E-04 | 1.656E-03 | BCL2, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.405E-04 | 2.097E-03 | SMAD3, PIM1, BCL2, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 5.469E-05 | 6.604E-04 | FABP3, FABP4, FABP5, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.560E-04 | 2.795E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 3.480E-04 | 2.795E-03 | CSNK2A1, BCL2, CDK1, NFKB1, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.044E-04 | 2.005E-03 | HPGD, FLT3, MET, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.021E-03 | 6.201E-03 | DNMT1, FUT7, HSD17B2, CYP1A2, ALOX15, CYP1A1, AKR1B1, ALOX12, PGD, TYR, HSD17B10 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 6.832E-04 | 4.875E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 9.677E-04 | 6.201E-03 | SMAD3, SRC, BCL2, NFKB1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.343E-04 | 2.097E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 6.693E-04 | 4.875E-03 | FLT3, PIM1, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 9.390E-04 | 6.201E-03 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.027E-03 | 6.201E-03 | SMAD3, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.269E-03 | 7.116E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.073E-03 | 6.238E-03 | FLT3, MET, EGFR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.375E-03 | 7.445E-03 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; FFAR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; FFAR1; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; BCL2; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| NA: NA | Christmas disease | NA | F10; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; ABCB1; F2; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; EGFR; SRC; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; INSR; EGFR; BCL2; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; EGFR; SRC; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; EGFR; ABCB1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; F2; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; DNMT1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| NA: NA | Haemophilia B | NA | F10; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; TEK; DNMT1; EGFR; SRC; ABCB1; F2; BCL2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; ABCB1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; EGFR; BCL2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; DNMT1; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; BCL2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; SRC; BCL2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
